Psychometric validation of the Weiss Functional Impairment Rating Scale-Parent Report Form in children and adolescents with attention-deficit/hyperactivity disorder

[1]  Joel L. Young.  Guanfacine Extended Release in Adolescents With ADHD: A Multicenter, Randomized, Placebo-Controlled Trial , 2014 .

[2]  T. Banaschewski,et al.  Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder , 2014 .

[3]  T. Banaschewski,et al.  European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder , 2013, European Neuropsychopharmacology.

[4]  J. Newcorn,et al.  Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration. , 2013, Journal of the American Academy of Child and Adolescent Psychiatry.

[5]  D. Coghill,et al.  Efficacy and Safety of Lisdexamfetamine Dimesylate and Atomoxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder: a Head-to-Head, Randomized, Double-Blind, Phase IIIb Study , 2013, CNS Drugs.

[6]  T. Banaschewski,et al.  Health-Related Quality of Life and Functional Outcomes from a Randomized, Controlled Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention Deficit Hyperactivity Disorder , 2013, CNS Drugs.

[7]  Janet B W Williams,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[8]  A. Hareendran,et al.  Development of a conceptual disease model to inform strategy to evaluate treatment impact in adolescents with attention deficit hyperactivity disorder (ADHD) , 2013 .

[9]  R. Findling,et al.  A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. , 2013, Journal of child and adolescent psychopharmacology.

[10]  R. Weisler,et al.  Randomized Clinical Study of a Histamine H3 Receptor Antagonist for the Treatment of Adults with Attention-Deficit Hyperactivity Disorder , 2012, CNS Drugs.

[11]  R. Findling,et al.  Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design. , 2012, The Journal of clinical psychiatry.

[12]  O. Ukoumunne,et al.  Relationship between symptoms of attention-deficit/hyperactivity disorder and family functioning: a community-based study , 2012, European Journal of Pediatrics.

[13]  S. Aryal,et al.  Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. , 2011, Journal of child and adolescent psychopharmacology.

[14]  V. Roessner,et al.  Relationship between quality of life and psychopathological profile: data from an observational study in children with ADHD , 2011, European Child & Adolescent Psychiatry.

[15]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[16]  C. Blanco,et al.  The lifetime impact of attention deficit hyperactivity disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) , 2011, Psychological Medicine.

[17]  J. Goulardins,et al.  Quality of life and psychomotor profile of children with attention deficit hyperactivity disorder (ADHD). , 2011, Arquivos de neuro-psiquiatria.

[18]  S. Segal,et al.  Clonidine Extended-Release Tablets as Add-on Therapy to Psychostimulants in Children and Adolescents With ADHD , 2011, Pediatrics.

[19]  R. Findling,et al.  Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. , 2011, Journal of the American Academy of Child and Adolescent Psychiatry.

[20]  S. Segal,et al.  Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. , 2011, Journal of the American Academy of Child and Adolescent Psychiatry.

[21]  P. Wehmeier,et al.  Quality of Life and Attention-Deficit/Hyperactivity Disorder Core Symptoms: A Pooled Analysis of 5 Non-US Atomoxetine Clinical Trials , 2010, Journal of clinical psychopharmacology.

[22]  R. Barkley,et al.  Social and emotional impairment in children and adolescents with ADHD and the impact on quality of life. , 2010, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[23]  J. Buitelaar,et al.  The quality of life of children with attention deficit/hyperactivity disorder: a systematic review , 2009, European Child & Adolescent Psychiatry.

[24]  D. Patrick,et al.  The use of patient-reported outcomes instruments in registered clinical trials: evidence from ClinicalTrials.gov. , 2009, Contemporary clinical trials.

[25]  I. Moilanen,et al.  Association between ADHD symptoms and adolescents' psychosocial well-being: a study of the Northern Finland Birth Cohort 1986 , 2009, International journal of circumpolar health.

[26]  E. Parens,et al.  Facts, values, and Attention-Deficit Hyperactivity Disorder (ADHD): an update on the controversies , 2009, Child and Adolescent Psychiatry and Mental Health.

[27]  B. Horta,et al.  The worldwide prevalence of ADHD: a systematic review and metaregression analysis. , 2007, The American journal of psychiatry.

[28]  U. S. Department of Health and Human Services FDA Cen Research,et al.  Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance , 2006, Health and quality of life outcomes.

[29]  S. Faraone,et al.  Symptoms versus impairment: the case for respecting DSM-IV's Criterion D. , 2005, Journal of attention disorders.

[30]  M. Boaz,et al.  Attention deficit and hyperactivity disorder/learning disabilities (ADHD/LD): parental characterization and perception. , 2005, Patient education and counseling.

[31]  V. Harpin,et al.  The effect of ADHD on the life of an individual, their family, and community from preschool to adult life , 2005, Archives of Disease in Childhood.

[32]  J. Currie,et al.  Child Mental Health and Human Capital Accumulation: The Case of Adhd , 2004, Journal of health economics.

[33]  Andrew E. Skodol,et al.  DSM-IV-TR Casebook: A Learning Companion to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision , 2001 .

[34]  W. Pelham,et al.  Attention-deficit hyperactivity disorder and problems in peer relations: predictions from childhood to adolescence. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[35]  M. Dulcan,et al.  Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[36]  G. Guyatt,et al.  Practice guidelines , 1996, Journal of General Internal Medicine.

[37]  I. Wilson,et al.  Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. , 1995, JAMA.

[38]  B. Price.  A First Course in Factor Analysis , 1993 .

[39]  R. Barkley,et al.  Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: a 3- to 5-year follow-up survey. , 1993, Pediatrics.

[40]  M. Browne,et al.  Alternative Ways of Assessing Model Fit , 1992 .

[41]  P. Bentler,et al.  Comparative fit indexes in structural models. , 1990, Psychological bulletin.

[42]  J. Fleiss,et al.  Intraclass correlations: uses in assessing rater reliability. , 1979, Psychological bulletin.

[43]  Jacob Cohen.  Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[44]  Howard B. Lee,et al.  Foundations of Behavioral Research , 1965 .

[45]  D. Campbell,et al.  Convergent and discriminant validation by the multitrait-multimethod matrix. , 1959, Psychological bulletin.

[46]  L. Cronbach.  Coefficient alpha and the internal structure of tests , 1951 .

[47]  B. Robertson,et al.  EPA-0685 – Guanfacine XR (GXR) for Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD): Phase 3, Randomized, Double-Blind, Multicenter, Placebo- and Active-Reference Study , 2014, European psychiatry.

[48]  V. Harpin,et al.  EPA-0666 – Long-term Maintenance of Efficacy of Extended-Release Guanfacine Hydrochloride (GXR) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD): Double-Blind, Placebo-Controlled, Multicentre, Phase 3 Randomized Withdrawal Study , 2014, European psychiatry.

[49]  H. Fisher,et al.  EPA-1645 – The Impact of Cannabis Use on Clinical Presentation in First-episode Psychosis: Adolescent- Versus Adult-onset Psychosis , 2014, European psychiatry.

[50]  T. Wilens,et al.  A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. , 2012, Journal of the American Academy of Child and Adolescent Psychiatry.

[51]  Guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder , 2010 .

[52]  David Evans,et al.  Book review - Learning Disabilities: Theories, Diagnosis and Teaching Strategies (9th ed.) 2003. J. Lerner Boston, MA: Houghton Mifflin , 2004 .

[53]  R. Hu.  Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) , 2003 .

[54]  B. Zumbo.  A Handbook on the Theory and Methods of Differential Item Functioning (DIF) LOGISTIC REGRESSION MODELING AS A UNITARY FRAMEWORK FOR BINARY AND LIKERT-TYPE (ORDINAL) ITEM SCORES , 1999 .

[55]  P. Bentler,et al.  Cutoff criteria for fit indexes in covariance structure analysis : Conventional criteria versus new alternatives , 1999 .

[56]  J. Epstein,et al.  Conners Rating Scales-Revised. , 1999 .

[57]  Robert Reid,et al.  Adhd Rating Scale-IV: Checklists, Norms, and Clinical Interpretation , 1998 .

[58]  C. Conners.  Conners' rating scales-revised : technical manual , 1997 .

[59]  Programmierbarer Thermoblock,et al.  From industry , 1991 .

[60]  G H Guyatt,et al.  Responsiveness and validity in health status measurement: a clarification. , 1989, Journal of clinical epidemiology.

[61]  Brämer Gr.  International statistical classification of diseases and related health problems. Tenth revision. , 1988, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.

[62]  J. Lerner.  Learning disabilities : theories, diagnosis, and teaching strategies / Janet W. Lerner , 1981 .

[63]  Howard B. Lee,et al.  A First Course in Factor Analysis 2nd Ed , 1973 .